ABCL Insider Trading Activity and SEC Form 4 Filings
ABCL insider trading summary
Over the past 12 months, insiders at AbCellera Biologics Inc. (ABCL) reported 7 open-market purchases worth $2.0M by 4 insiders and no sales on SEC Form 4. Net insider buying was $2.0M.
Latest ABCL insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 24, 2026 | Michael R Hayden | Director | Buy | $570K (53,613 @ $10.64) |
| Aug 18, 2026 | John S. Montalbano | Director | Buy | $110K (10,000 @ $11.03) |
| Aug 14, 2026 | Andrew Booth | Chief Financial Officer | Buy | $384K (37,200 @ $10.32) |
| Aug 12, 2026 | Michael R Hayden | Director | Buy | $481K (46,387 @ $10.37) |
| Feb 27, 2026 | Thermopylae Holdings Ltd. | 10% Owner | Buy | $131K (38,000 @ $3.44) |
| Feb 27, 2026 | Andrew Booth | Chief Financial Officer | Buy | $146K (42,600 @ $3.42) |
| Nov 26, 2025 | John S. Montalbano | Director | Buy | $178K (50,000 @ $3.57) |
| Mar 11, 2025 | Thermopylae Holdings Ltd. | 10% Owner | Buy | $742K (343,631 @ $2.16) |
| Mar 10, 2025 | John S. Montalbano | Director | Buy | $57K (25,000 @ $2.30) |
| Mar 6, 2025 | John S. Montalbano | Director | Buy | $141K (60,000 @ $2.34) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.